IOL Chemicals Q1 FY27: Revenue up 37%, PAT doubles

Key takeaway from the June 2026 quarter

IOL Chemicals and Pharmaceuticals Limited reported a sharp year-on-year improvement in its June 2026 quarter (Q1 FY27), led by higher revenue and a stronger bottom line. Revenue from operations rose to ₹756.26 crore for the quarter ended June 30, 2026, compared with ₹551.69 crore in the same quarter last year. Profit for the period increased to ₹64.48 crore from ₹33.96 crore a year ago. The results indicate a materially stronger quarter versus the corresponding period in FY26, based on the numbers disclosed.

What the company reported for Q1 FY27

The company announced its financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026. On a standalone basis, revenue from operations was ₹756.26 crore, marking a 37% year-on-year rise from ₹551.69 crore. Profit for the period more than doubled to ₹64.48 crore from ₹33.96 crore. Basic and diluted EPS for the quarter was reported at ₹2.20, up from ₹1.16 in the year-ago quarter. The improvement was reflected across the primary headline metrics shared in the results summary.

Standalone and consolidated numbers mentioned

Alongside standalone performance, the shared data also included consolidated figures for Q1 FY27. Consolidated revenue was stated at ₹756.26 crore for the quarter, matching the standalone revenue figure cited. Consolidated profit after tax (PAT) was reported at ₹64.40 crore. Consolidated basic and diluted EPS was listed at ₹2.19. The close alignment between standalone and consolidated figures suggests limited differences for the quarter in the numbers cited.

Segment performance: pharma and chemicals

The company also reported segment-wise standalone performance for the quarter. The pharmaceutical segment recorded revenue of ₹469.49 crore, with profit before tax (PBT) and interest of ₹68.81 crore. The chemical segment recorded revenue of ₹364.96 crore, with PBT and interest of ₹17.32 crore. These segment disclosures provide additional context on where revenue and profitability were generated within the business lines.

Quarter-on-quarter context available in the data

A sequential comparison was also referenced using the March 2026 quarter numbers. Consolidated revenue for Q1 FY27 was described as up 22.1% quarter-on-quarter from ₹619.45 crore. Separately, quarterly sales data showed ₹619.45 crore for Mar 2026 and ₹551.69 crore for Jun 2025, helping frame the year-on-year and quarter-on-quarter movement around the Q1 FY27 revenue figure. While the company’s detailed drivers were not provided in the text, the disclosed progression shows a step-up from the immediately preceding quarter.

Broader FY26 and FY25 financial backdrop

The provided information also included full-year figures for FY26 and FY25. For FY26, revenue was reported at ₹2,340.44 crore versus ₹2,101.62 crore in FY25, an 11.36% increase. Operating profit was reported at ₹184.36 crore in FY26 versus ₹137.96 crore in FY25, up 33.63%. Net profit was stated at ₹137.64 crore in FY26 versus ₹101.07 crore in FY25, an increase of 36.18%. These figures add a longer-period reference around the Q1 FY27 jump.

Corporate actions and upcoming schedule

A board meeting schedule was also mentioned in the shared note. The board meeting to consider and approve the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27) was scheduled for Monday, 10th August 2026. The trading window was stated to have been closed since 1st July 2026 and was expected to reopen on the 13th, as per the partial note shared. Such timelines matter for investors tracking disclosures and compliance-related trading restrictions.

Capital structure and identifiers shared

The data also included the company’s paid-up equity share capital and market-related identifiers. Paid-up equity share capital, with face value ₹2 per share, was stated at ₹58.71 crore. Market capitalisation was cited at ₹4,925.39 crore in the shared summary. The stock symbol was noted as IOLCP on the NSE and 524164 on the BSE, with ISIN INE485C01029. These details help investors map the results to the correct listed security.

Summary table of key reported metrics

Segment snapshot for Q1 FY27

Why the Q1 FY27 update matters for investors

The quarter’s disclosures show a clear acceleration in revenue growth and a sharp improvement in profit compared with the same period last year. The EPS increase to ₹2.20 from ₹1.16 highlights that the profit growth translated into higher per-share earnings for the quarter. Segment data indicates that the pharmaceutical segment contributed the larger share of standalone revenue for the quarter, while both segments reported positive PBT and interest numbers. For investors, the combination of year-on-year growth, sequential revenue improvement versus ₹619.45 crore in Mar 2026, and the published board meeting timeline forms the core set of facts to track.

Conclusion

For Q1 FY27 (ended June 30, 2026), IOL Chemicals and Pharmaceuticals reported revenue from operations of ₹756.26 crore and profit of ₹64.48 crore, with EPS at ₹2.20. Consolidated revenue and PAT were reported at ₹756.26 crore and ₹64.40 crore, respectively. Segment-wise, pharmaceuticals reported ₹469.49 crore revenue and chemicals ₹364.96 crore. The next formal step referenced in the shared information was the board meeting scheduled on 10th August 2026 to consider and approve unaudited results for the quarter ended June 30, 2026.